Point-of-care genetic profiling and/or platelet function testing in acute coronary syndrome.

Area of Science:

• Pharmacogenomics
• Cardiovascular Medicine
• Clinical Pharmacology

Background:

• Acute coronary syndrome (ACS) management involves P2Y12 inhibitors like clopidogrel and prasugrel.
• CYP2C19 genetic variations influence clopidogrel metabolism and efficacy.
• Platelet function testing (PFT) assesses antiplatelet therapy response.

Purpose of the Study:

• To evaluate if sequential genetic (CYP2C19) and platelet function testing optimizes P2Y12 inhibition in ACS patients.
• To compare P2Y12 inhibition levels between rapid and slow CYP2C19 metabolizers on clopidogrel and prasugrel.
• To assess the impact of switching antiplatelet agents based on genetic and functional testing.

Main Methods:

• Verigene® rapid CYP2C19 genetic test and VerifyNow™ PFT were used sequentially.
• Patients were categorized as rapid (CYP2C19*1/*1 or *17) or slow (CYP2C19*2) metabolizers.
• Initial therapy: clopidogrel (rapid) or prasugrel (slow) for ≥2 weeks, with subsequent drug switching based on PRU values.

Main Results:

• Initial non-inferiority comparison showed 71% of rapid metabolizers on clopidogrel and 56.9% of slow metabolizers on prasugrel within the target PRU range (30-208).
• After switching, 83.6% of rapid and 79.3% of slow metabolizers achieved the target PRU range.
• A weak correlation was observed between CYP2C19 genotype and platelet function phenotype, indicating their complementary roles.

Conclusions:

• Sequential genetic and platelet function testing aids in selecting optimal P2Y12 inhibitor (clopidogrel or prasugrel) for stented ACS patients.
• The combination of genotype and phenotype testing offers a more comprehensive approach to personalize antiplatelet therapy.
• This strategy may improve treatment outcomes by ensuring adequate P2Y12 inhibition.